Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma

Completed · Phase 2/Phase 3

Conditions studied: Melanoma, Neoplasm Metastasis

In brief

Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase. Subjects will be treated in repeating 4 week cycles.

Key facts

Study ID
NCT00055562
Run by
Celgene Corporation
People needed
274
Starts
2003-01-01
Expected to finish
2004-12-01
Last updated by the study team
2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.